ES2667049T3 - Derivados de heteroaril-[1,8]naftiridina - Google Patents

Derivados de heteroaril-[1,8]naftiridina Download PDF

Info

Publication number
ES2667049T3
ES2667049T3 ES10794897.8T ES10794897T ES2667049T3 ES 2667049 T3 ES2667049 T3 ES 2667049T3 ES 10794897 T ES10794897 T ES 10794897T ES 2667049 T3 ES2667049 T3 ES 2667049T3
Authority
ES
Spain
Prior art keywords
cyy
atoms
indicates
nyy
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10794897.8T
Other languages
English (en)
Spanish (es)
Inventor
Alfred Jonczyk
Dieter Dorsch
Guenter Hoelzemann
Christiane Amendt
Frank Zenke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Application granted granted Critical
Publication of ES2667049T3 publication Critical patent/ES2667049T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ES10794897.8T 2010-02-05 2010-12-17 Derivados de heteroaril-[1,8]naftiridina Active ES2667049T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10001251 2010-02-05
EP10001251 2010-02-05
PCT/EP2010/007743 WO2011095196A1 (en) 2010-02-05 2010-12-17 Hetaryl-[1,8]naphthyridine derivatives

Publications (1)

Publication Number Publication Date
ES2667049T3 true ES2667049T3 (es) 2018-05-09

Family

ID=43531801

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10794897.8T Active ES2667049T3 (es) 2010-02-05 2010-12-17 Derivados de heteroaril-[1,8]naftiridina

Country Status (14)

Country Link
US (2) US8614226B2 (enExample)
EP (1) EP2531500B1 (enExample)
JP (1) JP5675850B2 (enExample)
KR (1) KR20120124469A (enExample)
CN (1) CN102741249B (enExample)
AU (1) AU2010344973B2 (enExample)
BR (1) BR112012018954A2 (enExample)
CA (1) CA2789021C (enExample)
EA (1) EA201201081A1 (enExample)
ES (1) ES2667049T3 (enExample)
MX (1) MX2012008550A (enExample)
SG (1) SG182803A1 (enExample)
WO (1) WO2011095196A1 (enExample)
ZA (1) ZA201206630B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012019561A2 (pt) * 2010-02-22 2019-09-24 Merck Patent Gmbh hetarilamino naftiridinas
JP5826261B2 (ja) * 2010-06-28 2015-12-02 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 癌に対する使用のためのキナーゼ阻害剤としての２，４−ジアリール置換［１，８］ナフチリジン
WO2012006439A2 (en) * 2010-07-07 2012-01-12 Dow Agrosciences Llc Production of functionalized linear dna cassette and quantum dot/nanoparticle mediated delivery in plants
KR20130118612A (ko) * 2012-04-20 2013-10-30 (주)네오믹스 신규한 아미노피리딘 유도체 및 이의 용도
JP6457942B2 (ja) 2012-10-05 2019-01-23 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｇｄｆ−８阻害剤
US9550750B2 (en) 2012-10-05 2017-01-24 Merck Sharp & Dohme Corp. Indoline compounds as aldosterone synthase inhibitors
US9156831B2 (en) 2013-01-23 2015-10-13 Astrazeneca Ab Chemical compounds
CN103113369A (zh) * 2013-03-21 2013-05-22 云南大学 一种具有抗肿瘤活性的苯并[b][1,8]-萘啶-2-(1H)-亚胺衍生物及合成方法
TWI529171B (zh) * 2013-07-29 2016-04-11 赫孚孟拉羅股份公司 １，７－萘啶衍生物
JP6496731B2 (ja) 2013-11-27 2019-04-03 シグナルケム・ライフサイエンシーズ・コーポレイションＳｉｇｎａｌｃｈｅｍ Ｌｉｆｅｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｔａｍファミリーキナーゼ阻害剤としてのアミノピリジン誘導体
WO2015108881A1 (en) 2014-01-14 2015-07-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
TN2016000270A1 (en) * 2014-01-14 2017-10-06 Millennium Pharm Inc Heteroaryls and uses thereof.
JP6767875B2 (ja) * 2014-04-08 2020-10-14 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｔｇｆ−ベータ阻害剤としての２，３−二置換ピリジン化合物および使用方法
CR20200464A (es) 2018-03-08 2021-04-14 Incyte Corp Compuestos diólicos de aminopirazina como inhibidores de pi3k-y
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
CN115052663B (zh) 2020-01-08 2026-06-09 辛瑟斯治疗股份有限公司 Alk5抑制剂缀合物及其用途
AU2023294765A1 (en) * 2022-06-17 2024-12-12 Sundance Biosciences, Inc. Kinase modulators and methods of use thereof
WO2024258967A1 (en) 2023-06-13 2024-12-19 Synthis Therapeutics, Inc. Anti-cd5 antibodies and their uses

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR207555A1 (es) 1972-12-04 1976-10-15 Procedimiento para preparar aril-6-piperazinocarboniloxi-5 oxo-7 tetrahidro-2,3,6,7 ditiino(1,4)(2,3-c)pirroles
IT1245712B (it) * 1991-04-09 1994-10-14 Boehringer Mannheim Italia Ammine eterocicliche utili terapia dell'asma e dell'infiammazione delle vie aeree
US5994367A (en) * 1997-03-07 1999-11-30 The University Of North Carolina At Chapel Hill Method for treating tumors using 2-aryl-naphthyridin-4-ones
KR100607838B1 (ko) * 1997-10-27 2006-08-04 뉴로서치 에이/에스 니코틴 작용성 아세틸콜린 수용체상의 콜린 작용성 리간드로서의 호모피페라진 유도체 및 이를 포함하는 약제학적 조성물
EP1187633A4 (en) 1999-04-08 2005-05-11 Arch Dev Corp USE OF ANTI-VEGF ANTIBODIES TO ENHANCE RADIATION IN ANTICANCER THERAPY
GB0117060D0 (en) * 2001-07-12 2001-09-05 Merck Sharp & Dohme Therapeutic agents
AU2003229305A1 (en) * 2002-05-17 2003-12-02 Scios, Inc. TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-Beta INHIBITORS
DE602004014347D1 (de) * 2003-03-12 2008-07-24 Millennium Pharm Inc Chinazolin-derivate als tgf-beta-inhibitoren
TW200538120A (en) * 2004-02-20 2005-12-01 Kirin Brewery Compound having TGF-beta inhibitory activity and pharmaceutical composition containing same
MX2007010076A (es) * 2005-02-17 2007-10-16 Astellas Pharma Inc Derivado de heterociclico-1-carboxilato que contiene nitrogeno no aromatico de piridilo.
DE602006018354D1 (de) 2005-12-05 2010-12-30 Pfizer Prod Inc Verfahren zur behandlung von abnormalem zellwachstum
JP4751856B2 (ja) 2007-07-03 2011-08-17 本田技研工業株式会社 車体側部構造
DE102007049451A1 (de) 2007-10-16 2009-04-23 Merck Patent Gmbh 5-Cyano-thienopyridine
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
JP2011511005A (ja) 2008-02-04 2011-04-07 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド ２−アミノピリジン系キナーゼ阻害薬
DE102008017853A1 (de) 2008-04-09 2009-10-15 Merck Patent Gmbh Thienopyrimidine
EP2307402B1 (en) 2008-04-29 2012-11-07 Novartis AG Imidazo-pyridine derivatives as activin-like receptor kinase (alk4 or alk5) inhibitors
EP2445902A2 (en) * 2009-06-25 2012-05-02 Amgen, Inc Heterocyclic compounds and their uses as inhibitors of pi3k activity
BR112012019561A2 (pt) * 2010-02-22 2019-09-24 Merck Patent Gmbh hetarilamino naftiridinas
JP5826261B2 (ja) * 2010-06-28 2015-12-02 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 癌に対する使用のためのキナーゼ阻害剤としての２，４−ジアリール置換［１，８］ナフチリジン

Also Published As

Publication number Publication date
EP2531500A1 (en) 2012-12-12
US20140038960A1 (en) 2014-02-06
EA201201081A1 (ru) 2013-03-29
ZA201206630B (en) 2013-05-29
CA2789021C (en) 2018-02-06
CN102741249A (zh) 2012-10-17
EP2531500B1 (en) 2018-01-24
US8614226B2 (en) 2013-12-24
CN102741249B (zh) 2015-11-25
AU2010344973B2 (en) 2016-06-16
MX2012008550A (es) 2012-09-07
JP2013518832A (ja) 2013-05-23
US8912216B2 (en) 2014-12-16
US20120295902A1 (en) 2012-11-22
JP5675850B2 (ja) 2015-02-25
AU2010344973A1 (en) 2012-09-20
WO2011095196A1 (en) 2011-08-11
SG182803A1 (en) 2012-09-27
BR112012018954A2 (pt) 2016-04-12
KR20120124469A (ko) 2012-11-13
CA2789021A1 (en) 2011-08-11

Similar Documents

Publication Publication Date Title
EP2531500B1 (en) Hetaryl-[1,8]naphthyridine derivatives
JP6151919B2 (ja) ヘタリールアミノナフチリジン
ES2792799T3 (es) [1,8]naftiridinas 2,4-diaril-sustituidas como inhibidores de quinasas para su uso contra el cáncer
AU2022269566B2 (en) Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease
US20110212053A1 (en) Phosphatidylinositol 3 kinase inhibitors
KR20130025860A (ko) Ｔｇｆ-베타 수용체 키나아제 저해제로서의 헤테로아릴아미노퀴놀린
KR20130131293A (ko) 키나아제 - 유도된 질환의 치료에 유용한 바이피리딜 유도체
US9475812B2 (en) Pyridonaphthyridine type dual PI3K and mTOR inhibitor and its preparation and use
CN103596953A (zh) 吡啶并萘啶类P13K和mTOR双重抑制剂及其制备与应用
HK1177209A (en) Hetaryl-[1,8]naphthyridine derivatives
HK1185067A (en) Hetarylaminonaphthyridines
HK1173370A (en) Heteroarylaminoquinolines as tgf-beta receptor kinase inhibitors